Business Wire

MCR Acquires Cloud-Based Hotel Management Platform Optii

Share

MCR, the 4th-largest hotel owner-operator in the United States and one of Fast Company’s 10 Most Innovative Travel Companies of 2020, has acquired Optii, the only predictive, cloud-based technology for improved hotel operations.

Optii will continue to be a standalone company with its existing management team of CEO Katherine Grass, Founder and CSO Soenke Weiss and CRO Deborah Pevenstein.

MCR’s portfolio of 140 branded and independent hotels will be arms-length customers of Optii, which will continue to offer its product to forward-thinking hotel companies. No data will be shared with MCR. MCR will mobilize its 4,000 hotel team members — who will utilize Optii for 20,000 guestrooms per day — to push for innovative product enhancements.

Stayntouch property management system software, another standalone company owned by MCR, will integrate with Optii.

A data-driven platform powered by artificial intelligence, Optii has revolutionized housekeeping technology, optimizing labor and cleaning sequences for faster turnaround times and reduced costs. With its Service and Chat products, Optii streamlines internal communication, allowing managers to auto-assign and track jobs and guest requests in real time, eliminating calls by 95%. The user-friendly mobile and tablet interface can be accessed anywhere, whether on or off property.

Used by hotels to clean more than 10 million guestrooms globally, Optii has experienced stratospheric growth in the past year as hoteliers seek to increase housekeeping productivity while committing to Covid-19 protocols and facing labor shortages.

Fully configurable, the platform connects to many property management systems and is a best-in-class solution for hotels of all sizes, from 50-room boutique properties to 3,000-room casinos. Unlike any other hotel technology, remote onboarding is led by the experts — former executive housekeepers. The software’s artificial intelligence gets smarter over time — around week four, the technology peaks in providing operational efficiencies.

Optii has an aggressive expansion strategy that includes the imminent introduction of a Preventative Maintenance product.

Katherine Grass, CEO of Optii, says, “We are honored to have been selected by MCR to join their portfolio of companies. This acquisition will significantly boost our ability to provide hotels around the world with the technology they need to succeed in today’s operating environment. More and more hotels are realizing that investing in the right technology at this unique time can be a key lever for success. This is a huge growth opportunity for our company to continue momentum in the United States and Europe as well as to further develop our leadership position in Asia.”

Adds Tyler Morse, Chairman and CEO of MCR, “Innovation is a core value of MCR and the acquisition of Optii forwards our mission. At our 140 hotels, we have used every housekeeping technology on the market — and Optii is simply the best. MCR’s investment in Optii will expand its reach globally and provide the company with the resources to continue introducing cutting-edge technology to the hotel industry.”

About Optii Solutions

Optii, headquartered in Austin, Texas, and with offices in New York, London and Brisbane, is a hotel operations solution that leverages smarter technologies such as artificial intelligence, analytics, messaging and mobility to improve the efficiency and effectiveness of hotel operations teams. Optii operates in real time and allows hotels to streamline operations, reduce costs and enhance the guest experience in proven and tangible ways, without requiring capital expenditure and complex integrations. Optii is used by hotels around the world, including the Venetian Macau, part of Las Vegas Sands, La Cantera Resort & Spa and The Don Cesar in the United States, Okada Manilla Resort & Casino, Doma Hotels, Marriott, IHG and more. For further information about Optii, please visit optiisolutions.com.

About MCR

  • 4th-largest hotel owner-operator in the United States
  • $4.0 billion portfolio of 140 premium-branded hotels
  • MCR operates 8 Marriott brands, 6 Hilton brands and a number of unflagged independent hotels
  • 20,000 guestrooms across 34 states and 84 cities
  • Founded in 2006
  • Offices in New York City, Dallas, Chicago and Richmond, Virginia
  • 4,000 team members across the country
  • Three-time recipient of the Marriott Partnership Circle Award , the highest honor Marriott presents to its owner and franchise partners
  • Recipient of the Hilton Legacy Award for Top Performer
  • For the TWA Hotel at New York’s JFK Airport, MCR won the Development of the Year (Full Service) Award at The Americas Lodging Investment Summit (ALIS) , the Urban Land Institute New York Excellence in Hotel Development Award and the American Institute of Architects national Architecture Award, the highest honor given by the AIA
  • Named one of Fast Company’s 10 Most Innovative Travel Companies of 2020
  • For more information, please visit mcrhotels.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Ellie Box: ebox@fireoth.com, +44 7974 791119
Sarah Mulder: smulder@fireoth.com, +44 7720401466

info@mcrhotels.com
(203) 682-8277

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye